A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : ER / extended-release

[Related PubMed/MEDLINE]
Total Number of Papers: 968
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   ER  (>> Co-occurring Abbreviation)
Long Form:   extended-release
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 Effects of Diurnal Variation and Food on Gastrointestinal Transit of 111In-Labeled Hydrogel Matrix Extended-Release Tablets and 99mTc-Labeled Pellets in Humans. ---
2019 A Quantitative Comparison Approach for Methylphenidate Drug Regimens in Attention-Deficit/Hyperactivity Disorder Treatment. ADHD, IR, MPH, PK
2019 A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA. T2D
2019 Adherence, satisfaction, and experience with metformin 500 mg prolonged release formulation in Indian patients with type 2 diabetes mellitus: a postmarketing observational study. PR, T2DM
2019 Advances with extended and controlled release formulations of antiepileptics in the elderly. AEDs, IR
2019 Amphetamine extended-release oral suspension for attention-deficit/hyperactivity disorder. ADHD, AMPH
2019 An in vitro approach for evaluating the oral abuse deterrence of solid oral extended-release opioids with properties intended to deter abuse via chewing. AD
2019 An update on the pharmacokinetic considerations in the treatment of ADHD with long-acting methylphenidate and amphetamine formulations. ADHD, AMP, MPH
2019 Antimuscarinic use and discontinuation in an older adult population. IR
10  2019 Assessment of Taste and Grittiness of Riomet ER Strawberry, Riomet ER Grape, Riomet Cherry, and Metformin Immediate-Release Tablets in Healthy Subjects. IR
11  2019 Bioavailability and Pharmacokinetics of Once-Daily Amantadine Extended-Release Tablets in Healthy Volunteers: Results from Three Randomized, Crossover, Open-Label, Phase 1 Studies. IR, PK
12  2019 Comorbid anxiety in late-life depression: Relationship with remission and suicidal ideation on venlafaxine treatment. BSI, MDD
13  2019 Comparative pharmacokinetic evaluation of extended release itopride HCl pellets with once daily tablet formulation in healthy human subjects: a two treatment, four period crossover study in fasted and fed condition. OD, PKs
14  2019 Cost Comparison of Atypical Antipsychotics: Paliperidone ER and Risperidone. ---
15  2019 Cost Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in Colombia. COP, GDP, ICER, ISI, MSI, OAB, QALYs
16  2019 Development of In Vitro-In Vivo Correlation for Upadacitinib Extended-Release Tablet Formulation. IVIVC
17  2019 Dosing Requirements of Extended-Release Tacrolimus (Astagraf XL) in African American Kidney Transplant Recipients Converted from Immediate Release Tacrolimus (AAAKTRS). AAAKTRS, IR
18  2019 Effects on Satisfaction and Service Engagement of Paliperidone Palmitate Compared with Oral Paliperidone in Patients with Schizophrenia: An Open Label Randomized Controlled Trial. ANZCTR, CGI-SCH, PSP, SES, TSQM
19  2019 Efficacy and safety of memantine in children with autism spectrum disorder: Results from three phase 2 multicenter studies. ---
20  2019 Evaluating the Clinical Impact of Formulation Variability: A Metoprolol Extended-Release Case Study. EIHR
21  2019 Evaluation of Abuse and Route of Administration of Extended-Release Tapentadol Among Treatment-Seeking Individuals, as Captured by the Addiction Severity Index-Multimedia Version (ASI-MV). ASI-MV, FDA
22  2019 Evaluation of commercially available meth-deterrent pseudoephedrine hydrochloride products. IR, OTC, PSE
23  2019 Evaluation of real-world persistence of propiverine and trospium chloride in treatment of overactive bladder in Germany. IR, OAB
24  2019 Exposure-Response Analyses for Upadacitinib Efficacy and Safety in the Crohn's Disease CELEST Study and Bridging to the Extended-Release Formulation. CD, IR
25  2019 Extended release levodopa at bedtime as a treatment for nocturiain Parkinson's disease: An open label study. NQoL, PD
26  2019 Extended-Release Amantadine for Levodopa-Induced Dyskinesia. LID, PD
27  2019 Impact of Abuse Deterrent Formulations of Opioids in Patients With Chronic Pain in the United States: A Cost-Effectiveness Model. ADF
28  2019 Injection moulded controlled release amorphous solid dispersions: Synchronized drug and polymer release for robust performance. ASD, DC, IM, PEO
29  2019 Lurasidone compared to other atypical antipsychotic monotherapies for adolescent schizophrenia: a systematic literature review and network meta-analysis. CGI-S, EPS, ORs, PANSS
30  2019 Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting. GLP-1, NMA, T2D
31  2019 Medical Use of Long-term Extended-release Opioid Analgesics in Commercially Insured Adults in the United States. ---
32  2019 Mitigation of IV Abuse Through the Use of Abuse-Deterrent Opioid Formulations: An Overview of Current Technologies. ADFs, LA
33  2019 Novel extended in vitro-in vivo correlation model for the development of extended-release formulations for baclofen: From formulation composition to in vivo pharmacokinetics. HPMC, IVIVC
34  2019 Paliperidone Extended-Release Tablets for the Treatment of Methamphetamine Use Disorder in Chinese Patients After Acute Treatment: A Randomized, Double-Blind, Placebo-Controlled Exploratory Study. CGI-S, CI, HR, METH, PANSS
35  2019 Pharmacokinetic and Pharmacodynamic Correlations From 2 Studies Evaluating Abuse Potential of Hydrocodone Extended-Release Tablets. AUC, Emax, PD, PK, tmax, VAS
36  2019 Pharmacokinetics and Bioequivalence Evaluation of a New Oxycodone Tamper-Resistant Tablet Administered with an Opioid Antagonist in Patients with Chronic Pain. OTR, OXY
37  2019 Pharmacokinetics and Pharmacodynamics of Immediate-Release Versus Extended-Release Guanfacine in Adult Daily Smokers. IR
38  2019 Pharmacokinetics of a commercially available product and a compounded formulation of extended-release levetiracetam after oral administration of a single dose in cats. ---
39  2019 Pharmacokinetics of Upadacitinib With the Clinical Regimens of the Extended-Release Formulation Utilized in Rheumatoid Arthritis Phase 3 Trials. IR, RA
40  2019 Population Pharmacokinetics of Pregabalin Extended-Release in Healthy Volunteers and Patients With Postherpetic Neuralgia, Fibromyalgia, and Partial-Onset Seizures. IR, PK
41  2019 Population Pharmacokinetics of Upadacitinib Using the Immediate-Release and Extended-Release Formulations in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I-III Clinical Trials. AUC, IR, JAK, RA
42  2019 Potential pharmacobezoar formation of large size extended-release tablets and their dissolution - an in vitro study. SGF
43  2019 Randomized placebo-controlled trial of galantamine in individuals with cocaine use disorder. CUD
44  2019 Recent Clinical Advances in Pharmacotherapy for Levodopa-Induced Dyskinesia. L-dopa
45  2019 Relapse prevention with levomilnacipran ER in adults with major depressive disorder: A multicenter, randomized, double-blind, placebo-controlled study. AEs, MADRS, MDD
46  2019 Risk assessment of phthalates in pharmaceuticals. DBP, DEHP, DEP, HI
47  2019 Safety And Tolerability Of Extended-Release Guaifenesin In Patients With Cough, Thickened Mucus And Chest Congestion Associated With Upper Respiratory Tract Infection. AEs, URTI
48  2019 Safety of Opioids in Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis. AEs, CI, GI, IR, OA, RR
49  2019 Switching to paliperidone extended release in patients with schizophrenia dissatisfied with previous olanzapine treatment: Post hoc analysis of an open-label, prospective study. CGI-S, PANSS, PSP
50  2019 Syringeability of morphine ARER, a novel, abuse-deterrent, extended-release morphine formulation. ---
51  2019 The effect of an interprofessional pain service on nonmalignant pain control. IR, MEDD, MTM
52  2019 The effectiveness of trospium for prevention of catheter-related bladder discomfort: a prospective, randomized, placebo-controlled, double-blind study. CRBD, OAB
53  2019 Triamcinolone Acetonide Extended-Release: A Review in Osteoarthritis Pain of the Knee. CS, IA, OA
54  2019 Variability of Retail Pricing of Generic Urologic Medications in a Major US Metropolitan Area. ---
55  2018 A Clinician's Guide to Oral Extended-Release Drug Delivery Systems in Epilepsy. AEDs, IR
56  2018 A Comparison of the Pharmacokinetics of Methylphenidate Extended-Release Orally Disintegrating Tablets With a Reference Extended-Release Formulation of Methylphenidate in Healthy Adults. MPH, MPH XR-ODT, PK, Tmax
57  2018 A Health Plan's Formulary Led To Reduced Use Of Extended-Release Opioids But Did Not Lower Overall Opioid Use. ---
58  2018 A novel non-opioid protocol for medically supervised opioid withdrawal and transition to antagonist treatment. COWS, SUD
59  2018 A pharmacokinetic drug-drug interaction study between pregabalin and tramadol in healthy volunteers. GMR, PK
60  2018 Abuse of immediate-release opioids and current approaches to reduce misuse, abuse, and diversion. IR
61  2018 Amantadine Extended-Release (GOCOVRI™): A Review in Levodopa-Induced Dyskinesia in Parkinson's Disease. AEs, LID, PD, UDysRS
62  2018 An evaluation of memantine ER + donepezil for the treatment of Alzheimer's disease. AD, FDA
63  2018 Analgesic efficacy, safety, and tolerability of a long-acting abuse-deterrent formulation of oxycodone for moderate-to-severe chronic low back pain in subjects successfully switched from immediate-release oxycodone. IR
64  2018 Bioequivalence and Safety of Twice-Daily Sustained-Release Paracetamol (Acetaminophen) Compared With 3- and 4-Times-Daily Paracetamol: A Repeat-Dose, Crossover Pharmacokinetic Study in Healthy Volunteers. IR, SR
65  2018 Brand vs generic adverse event reporting patterns: An authorized generic-controlled evaluation of cardiovascular medications. AE, AGs, ROR
66  2018 Cardiovascular Outcomes with Once-Weekly GLP-1 RAs: Clinical and Economic Implications. ASCVD, GLP-1RAs, MACE, T2DM
67  2018 Change and dispersion of QT interval during treatment with quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: results from the TEA trial. HR, QTcH, QTd
68  2018 Clinical Efficacy of Once-weekly Glucagonlike Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes. CI, ETD, ETD, FPG, GLP-1RAs, OD, OW, T2D
69  2018 Cost-effectiveness of solifenacin compared with oral antimuscarinic agents for the treatment of patients with overactive bladder in the UK. ICER, IR, NHS, OAB, QALY
70  2018 Dosing Patterns during Conversion to IPX066, Extended-Release Carbidopa-Levodopa (ER CD-LD), in Parkinson's Disease with Motor Fluctuations. CD-LD, CLE, ER CD-LD, IR
71  2018 Effect of Concomitant Medications on the Safety and Efficacy of Extended-Release Carbidopa-Levodopa (IPX066) in Patients With Advanced Parkinson Disease: A Post Hoc Analysis. CD-LD, CLE, IR, MAO-B
72  2018 Effect of lipid and cellulose based matrix former on the release of highly soluble drug from extruded/spheronized, sintered and compacted pellets. CW, E-S, EC, GMS, HPMC, IR, RSM
73  2018 Effects of Education and Experience on Primary Care Providers' Perspectives of Obesity Treatments during a Pragmatic Trial. PCP-I, PCPs, SD
74  2018 Effects of tapentadol on pain, motor symptoms and cognitive functions in Parkinson's disease. PD
75  2018 Efficacy and safety of amantadine for the treatment of L-DOPA-induced dyskinesia. IR, LIDs, PD, RCTs
76  2018 Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial. ETD
77  2018 Efficacy and safety of twice daily sustained-release paracetamol formulation for osteoarthritis pain of the knee or hip: a randomized, double-blind, placebo-controlled, twelve-week study. GPAOA, OA, PGART, SR
78  2018 Efficacy, tolerability, and safety of oral paliperidone extended release in the treatment of schizophrenia: a 24-week, open-label, prospective switch study in different settings in Taiwan. ---
79  2018 Evaluation of Switching Patterns in FDA's Sentinel System: A New Tool to Assess Generic Drugs. ---
80  2018 Evaluation of the Relative Abuse of an OROS Extended-release Hydromorphone HCI Product: Results From 3 Postmarket Surveillance Studies. ROA
81  2018 Evaluation of the Relative Intranasal Abuse Potential of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users. ---
82  2018 Exceeding the maximum daily dose of acetaminophen with use of different single-ingredient OTC formulations. SI
83  2018 Extended-release drug formulations for the treatment of epilepsy. AEDs, IR
84  2018 Extended-Release Morphine for Chronic Breathlessness in Pulmonary Arterial Hypertension-A Randomized, Double-Blind, Placebo-Controlled, Crossover Study. PAH
85  2018 Fabrication and statistical optimization of starch-kappa-carrageenan cross-linked hydrogel composite for extended release pellets of zaltoprofen. Skappa-C
86  2018 Factors impacting the efficacy of venlafaxine extended release 75-225 mg/day in patients with major depressive disorder: exploratory post hoc subgroup analyses of a randomized, double-blind, placebo-controlled study in Japan. HAM-D17, MDD
87  2018 Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists. GLP-1RAs, OADs, T2DM
88  2018 Health-Related Quality of Life Assessments with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus. GLP-1RAs, HRQoL
89  2018 High-dose versus standard-dose amoxicillin/clavulanate for clinically-diagnosed acute bacterial sinusitis: A randomized clinical trial. HD, IR, SD
90  2018 Human abuse potential studies of abuse-deterrent opioids: lessons from oral and intranasal studies with morphine abuse-deterrent, extended-release, injection-molded tablets. AD, HAP
91  2018 Identifying prevalence and risk factors for metformin non-persistence: a retrospective cohort study using an electronic health record. ---
92  2018 Impact of opioid dose reduction on individuals with chronic pain: results of an online survey. CDC, IR, LA
93  2018 Intranasal Pharmacokinetics of Morphine ARER, a Novel Abuse-Deterrent Formulation: Results from a Randomized, Double-Blind, Four-Way Crossover Study in Nondependent, Opioid-Experienced Subjects. PK, tmax
94  2018 Long-Acting GLP-1 Receptor Agonist Exenatide Influence on the Autonomic Cardiac Sympatho-Vagal Balance. HR, HRV
95  2018 Low colonic absorption drugs: risks and opportunities in the development of oral extended release products. I-V, LCA
96  2018 Memantine ER Maintains Patient Response in Moderate to Severe Alzheimer's Disease: Post Hoc Analyses From a Randomized, Controlled, Clinical Trial of Patients Treated With Cholinesterase Inhibitors. ADL, ChEI, CIBIC-Plus, NPI, SIB
97  2018 Meta-analysis of the adverse events associated with extended-release versus standard immediate-release pramipexole in Parkinson disease. IR, MJs, PD, RR
98  2018 Novel Extended-Release Multiple-Unit System of Imidafenacin Prepared by Fluid-Bed Coating Technique. IDN
99  2018 Opana ER (Oxymorphone)-Induced Thrombotic Microangiopathy: An Atypical Presentation in a Patient With Hepatitis C. TMA
100  2018 Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER). EOT, HRQoL, MID, OAB, OAB-S, PPBC, PROs